E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia

Leukemia

Volumn 31, Issue 2, 2017, Pages 502-505

  Park, I K ^a,b   Blum, W ^b   Baker, S D ^a,b   Caligiuri, M A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CD135 ANTIGEN; E3 UBIQUITIN LIGASE CBL B; MIDOSTAURIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; REGULATOR PROTEIN; SIVA 1 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CBL PROTEIN; SIVA1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ACUTE MYELOID LEUKEMIA; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIVISION; CELL GROWTH; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; LETTER; LONG TERM SURVIVAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS REGULATORY PROTEINS; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTO-ONCOGENE PROTEINS C-CBL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84995752374     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.293     Document Type: Letter

References (16)

1. Sudhindra A, Smith CC. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014; 9: 174-185.
2. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009; 12: 81-89.
3. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-873.
4. Sasca D, Hahnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 2014; 124: 121-133.
5. Li L, Osdal T, Ho YW, Chun S, McDonald T, Agarwal P et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell 2014; 15: 431-446.
6. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
7. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M et al. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012; 97: 1722-1730.
8. Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 2012; 120: 1130-1136.
9. Liyasova MS, Ma K, Lipkowitz S.. Molecular pathways: Cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment. Clin Cancer Res 2015; 21: 1789-1794.
10. Oshikawa G, Nagao T, Wu N, Kurosu T, Miura O. c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. J Biol Chem 2011; 286: 30263-30273.
11. Chen D, Yoon JB, Gu W. Reactivating the ARF-p53 axis in AML cells by targeting ULF. Cell Cycle 2010; 9: 2946-2951.
12. Wang X, Zha M, Zhao X, Jiang P, Du W, Tam AY et al. Siva1 inhibits p53 function by acting as an ARF E3 ubiquitin ligase. Nat Commun 2013; 4: 1551.
13. Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine JC et al. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther 2011; 10: 983-993.
14. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-1334.
15. Van Nostrand JL, Brisac A, Mello SS, Jacobs SB, Luong R, Attardi LD. The p53 target gene SIVA enables non-small cell lung cancer development. Cancer Discov 2015; 5: 622-635.
16. Andreeff M, Kelly KR, Yee KW, Assouline SE, Strair R, Popplewell L et al. Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia. Clin Cancer Res 2015; 22: 868-876.